These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35247086)

  • 1. Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
    Bagegni NA; Park H; Kraft K; O-Toole M; Gao F; Waqar SN; Ratner L; Morgensztern D; Devarakonda S; Amin M; Baggstrom MQ; Liang C; Selvaggi G; Wang-Gillam A
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):487-497. PubMed ID: 35247086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
    Pedersen KS; Grierson PM; Picus J; Lockhart AC; Roth BJ; Liu J; Morton A; Chan E; Huffman J; Liang C; Wang-Gillam A; Tan B
    Invest New Drugs; 2021 Oct; 39(5):1298-1305. PubMed ID: 33738668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.
    Sheng X; Yan X; Chi Z; Cui C; Si L; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Ding L; Mao L; Guo J
    EBioMedicine; 2020 May; 55():102755. PubMed ID: 32335374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
    Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
    Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
    Zhang B; Liu H; Shi C; Gao Z; Zhong R; Gu A; Chu T; Wang H; Xiong L; Zhang W; Zhang X; Yan B; Teng J; Wang W; Bai H; Qiao R; Cheng L; Kuang Y; Zhao R; Zhong H; Han B
    BMC Cancer; 2024 Jun; 24(1):715. PubMed ID: 38862908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.
    Beckermann KE; Bestvina CM; El Osta B; Sanborn RE; Borghaei H; Lammers PE; Selvaggi G; Whisenant JG; Heimann-Nichols E; Berry L; Hsu CY; Shyr Y; Horn L; Wakelee H
    JTO Clin Res Rep; 2024 Feb; 5(2):100619. PubMed ID: 38328473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
    Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
    Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
    Hong DS; Postow M; Chmielowski B; Sullivan R; Patnaik A; Cohen EEW; Shapiro G; Steuer C; Gutierrez M; Yeckes-Rodin H; Ilaria R; O'Connell B; Peng J; Peng G; Zizlsperger N; Tolcher A; Wolchok JD
    Clin Cancer Res; 2023 Jun; 29(12):2210-2219. PubMed ID: 37000164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial.
    Song Y; Wang J; Ren X; Jin J; Mao L; Liang C; Ding L; Yang L
    Chin J Cancer Res; 2021 Feb; 33(1):103-114. PubMed ID: 33707933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors.
    Bendell JC; Patel MR; Moore KN; Chua CC; Arkenau HT; Dukart G; Harrow K; Liang C
    Oncologist; 2019 Apr; 24(4):455-e121. PubMed ID: 30478190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the
    Kim C; Liu SV; Subramaniam DS; Torres T; Loda M; Esposito G; Giaccone G
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
    Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
    BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
    Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
    JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
    Gong J; Cao J; Zhang Q; Xu N; Zhao Y; Xing B; Miao Z; Wu Y; Pan H; Gao Q; Li X; Liu B; Li W; Pei Z; Xia H; Qi Q; Dai H; Shi Q; Yang J; Li J; Shen L
    Cancer Immunol Immunother; 2022 Aug; 71(8):1897-1908. PubMed ID: 34984540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.